Cargando…
Bone loss and the aromatase inhibitors
The increasing use of systemic adjuvant therapies has considerably improved the prognosis from early breast cancer. However, some of these therapies affect bone metabolism, resulting in osteoporosis. Aromatase inhibitors lower circulating oestrogen levels to almost unrecordable levels in postmenopau...
Autores principales: | Lester, J, Coleman, R |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2005
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361688/ https://www.ncbi.nlm.nih.gov/pubmed/16100521 http://dx.doi.org/10.1038/sj.bjc.6602691 |
Ejemplares similares
-
Sequencing of aromatase inhibitors
por: Bertelli, G
Publicado: (2005) -
Role of aromatase inhibitors in breast cancer
por: Carpenter, R, et al.
Publicado: (2005) -
The effects of aromatase inhibitors on lipids and thrombosis
por: Bundred, N J
Publicado: (2005) -
Potential use of COX-2–aromatase inhibitor combinations in breast cancer
por: Bundred, N J, et al.
Publicado: (2005) -
The World Health Organization and Global Health Governance: post-1990
por: Lidén, J.
Publicado: (2014)